About US
Contact us
-
More Valeant up for bid? Beseiged pharma weighs $2.5B sale of eye-surgery bizAnother day, another Valeant asset sale rumor. Less than 24 hours after word got out that Valeant and Takeda were in Salix deal talks, the embattled drugmaker is said to be exploring a sale of its eye2016/10/27
-
ASHLAND INDUSTRIES NEDERLAND’S ZWIJNDRECHT SITE RECEIVESNEWS RELEASEASHLAND INDUSTRIES NEDERLAND’S ZWIJNDRECHT SITE RECEIVESEXCiPACT GMP CERTIFICATION AS PHARMACEUTICAL EXCIPIENTSUPPLIERSBrussels, 25 October 2016EXCiPACT asbl is delighted to announce that2016/10/26
-
J&J pushes to move talcum powder cancer lawsuits to NJ, where it's won twoAt least 18 federal lawsuits claiming Johnson & Johnson’s ($JNJ) talc-based powders caused ovarian cancer could be consolidated for pretrial work, and J&J wants that litigation in New Jersey,2016/10/26
-
Colombia makes good on Gleevec pricing threat with plans for 45% cutA tense, months-long pricing standoff with Novartis escalated late last week as Colombia decided to take the radical step it had been threatening: The country plans to cut the price of leukemia med Gl2016/10/25
-
Sanofi lawsuit tries to hold Merck Lantus biosimilar at bayJust because Sanofi negotiated a settlement that allows Eli Lilly to launch its Lantus biosimilar injectorin mid-December does not mean the French drugmaker is prepared to cede U.S. market share to an2016/10/25
-
Mylan CEO faces grilling on Capitol Hill as senators unveil price-hike legislationThe EpiPen drama is moving into a congressional hearing room. Mylan CEO Heather Bresch is on the docket to testify next Wednesday for the House Committee on Oversight and Government Reform, where she’2016/10/24
-
Teva's trying to weasel out of its Mexican generics deal, new Rimsa lawsuit saysTurns out Teva didn’t quite know what it was getting itself into when it agreed to buy out Mexico’s Rimsa last year for $2.3 billion. The Israeli generics giant is suffering “buyer’s remorse” and loo2016/10/24
-
Milo Biotechnology receives orphan drug designation for AAV1-FS344 to treat inclusion body myositisMilo Biotechnology has secured Orphan Drug designation for its AAV1-FS344 from the Federal Drug Administration’s (FDA) Office of Orphan Products Development for treatment of inclusion body myositis.2016/10/21
-
US FDA grants breakthrough therapy designation to AbbVie's G/P to treat HCVAbbVie's investigational, pan-genotypic regimen of glecaprevir (ABT-493) / pibrentasvir (ABT-530) (G/P) has received breakthrough therapy designation from the US Food and Drug Administration (FDA) to2016/10/21
-
US FDA grants approval for Novartis' Ilaris to treat Periodic Fever SyndromesNovartis has received the US Food and Drug Administration's (FDA) approval for Ilaris (canakinumab) to treat rare Periodic Fever Syndrome conditions. Periodic Fever Syndromes are a group of diseases2016/10/20